Sociedad Americana de Hirudoterapia

Bundesinstitut für Arzneimittel und Medizinprodukte

BfArM · Germany · europe

Regulatory jurisdiction profileJurisdictional reference
Drug-classifiednational regulator

Germany classifies medicinal leeches as a finished medicinal product (Fertigarzneimittel) — uniquely strict among EU Member States and requires marketing authorisation via BfArM.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Germany
Leech status
drug classified
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Arzneimittelgesetz (AMG) — Medicines Act, § 21 (Marketing Authorisation)
  • Apothekenbetriebsordnung (ApBetrO) — Pharmacy Operations Ordinance
  • Heilpraktikergesetz (HeilprG) of 1939 (governs non-physician practice)

Prescriber Requirements

  • Physician (Arzt) prescription strongly recommended; medicinal-product status means leeches are dispensed via Apotheke (pharmacy)
  • Heilpraktiker (state-licensed non-physician healers) have legal scope to apply leeches under HeilprG
  • Hirudotherapy training is offered by Deutscher Naturheilbund and Kneipp-Bund; not a federally credentialed specialty

Supply Chain & GMP

Marketing authorisation holder must operate to EU-GMP and § 13 AMG manufacturing licence. Pharmacies receive leeches in approved transport (PZN-tagged). Cold chain 4–10 °C; storage water specifications in product monograph.

Import/Export Rules

Intra-EU free movement once AMG-approved. Import from third countries requires § 72 AMG import licence and PEI (Paul-Ehrlich-Institut) consultation. CITES paperwork as elsewhere.

Reimbursement Context

GKV (Gesetzliche Krankenversicherung / statutory health insurance) covers leech therapy for arthrosis indications under § 137c SGB V (selected G-BA-approved diagnoses) and inpatient flap salvage. PKV (private) commonly reimburses by GOÄ digit 250–252 / 268.

ASH Editorial Notes

Germany is the only major EU jurisdiction that treats leeches as a finished medicinal product rather than a medical device. BIEBERTAL (Biebertaler Blutegelzucht GmbH) is the principal German producer; second to Biopharm in European supply.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.